Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIXNYSE:CVMNASDAQ:EXOZNASDAQ:MGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$2.70-1.1%$2.86$2.07▼$4.20$86.93M0.5295,859 shs30,785 shsCVMCEL-SCI$0.29+1.0%$0.29$0.18▼$2.39$24.40M0.951.04 million shs1.21 million shsEXOZExozymes$12.05-10.9%$13.35$8.50▼$23.99$100.83MN/A19,784 shs29,112 shsMGNXMacroGenics$1.79+4.7%$1.86$0.99▼$16.48$112.93M2.231.14 million shs831,177 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+0.37%-0.73%-14.69%-6.51%-11.07%CVMCEL-SCI+5.70%+11.53%+7.85%-26.60%-80.26%EXOZExozymes+14.76%+21.67%+3.20%+1,352,999,900.00%+1,352,999,900.00%MGNXMacroGenics+12.50%+44.92%-12.76%-45.89%-89.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences2.4342 of 5 stars3.64.00.00.00.63.30.0CVMCEL-SCIN/AN/AN/AN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AN/AN/AN/AMGNXMacroGenics3.5833 of 5 stars3.21.00.04.42.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.25Buy$9.00233.33% UpsideCVMCEL-SCI 0.00N/AN/AN/AEXOZExozymes 0.00N/AN/AN/AMGNXMacroGenics 2.36Hold$7.38312.01% UpsideCurrent Analyst Ratings BreakdownLatest CVM, MGNX, EXOZ, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/26/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/25/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/25/2025MGNXMacroGenicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $2.003/21/2025ANIXAnixa BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.002/18/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K413.96N/AN/A$0.59 per share4.58CVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AEXOZExozymesN/AN/AN/AN/AN/AN/AMGNXMacroGenics$148.34M0.76N/AN/A$2.46 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.39N/A∞N/AN/A-58.55%-53.29%6/3/2025 (Estimated)CVMCEL-SCI-$26.92M-$0.48N/AN/AN/AN/A-238.05%-104.65%N/AEXOZExozymesN/AN/A0.00∞N/AN/AN/AN/AN/AMGNXMacroGenics-$9.06M-$1.08N/AN/AN/A-69.07%-89.42%-38.57%5/8/2025 (Estimated)Latest CVM, MGNX, EXOZ, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MGNXMacroGenics-$0.61N/AN/AN/A$9.59 millionN/A3/20/2025Q4 2024MGNXMacroGenics-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 million3/11/2025Q1 2025ANIXAnixa Biosciences-$0.10-$0.10N/A-$0.10N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/ACVMCEL-SCIN/AN/AN/AN/AN/AEXOZExozymesN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.548.54CVMCEL-SCI0.661.071.09EXOZExozymesN/AN/AN/AMGNXMacroGenicsN/A3.753.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%CVMCEL-SCI12.08%EXOZExozymesN/AMGNXMacroGenics96.89%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%CVMCEL-SCI16.24%EXOZExozymesN/AMGNXMacroGenics11.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.20 million24.05 millionOptionableCVMCEL-SCI4384.12 million64.67 millionOptionableEXOZExozymes298.37 millionN/AN/AMGNXMacroGenics43063.09 million55.67 millionOptionableCVM, MGNX, EXOZ, and ANIX HeadlinesRecent News About These CompaniesHead-To-Head Contrast: MacroGenics (NASDAQ:MGNX) versus Ensysce Biosciences (NASDAQ:ENSC)April 22 at 2:43 AM | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Receives $7.38 Consensus Target Price from AnalystsApril 20, 2025 | americanbankingnews.comWasatch Advisors LP Raises Stake in MacroGenics, Inc. (NASDAQ:MGNX)April 19, 2025 | marketbeat.com4 Medical Product Stocks to Buy From a Challenging IndustryApril 17, 2025 | zacks.comMacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of "Hold" from BrokeragesApril 17, 2025 | marketbeat.comMacroGenics (NASDAQ:MGNX) Stock Price Crosses Below Two Hundred Day Moving Average - What's Next?April 10, 2025 | marketbeat.comMacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerApril 3, 2025 | zacks.comQ1 Earnings Forecast for MacroGenics Issued By HC WainwrightMarch 28, 2025 | marketbeat.comWhy MacroGenics, Inc.’s (MGNX) Stock Is Down 12.85%March 27, 2025 | aaii.comMacroGenics (NASDAQ:MGNX) Price Target Lowered to $2.00 at HC WainwrightMarch 26, 2025 | marketbeat.comMacroGenics price target lowered to $2 from $4 at H.C. WainwrightMarch 25, 2025 | markets.businessinsider.comMacroGenics Provides Update on Corporate Progress and 2024 Financial ResultsMarch 22, 2025 | finance.yahoo.comQ4 2024 MacroGenics Inc Earnings CallMarch 21, 2025 | uk.finance.yahoo.comBarclays Sticks to Their Buy Rating for MacroGenics (MGNX)March 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Receives a Hold from Stifel NicolausMarch 21, 2025 | markets.businessinsider.comMacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer dataMarch 21, 2025 | fiercebiotech.comMacroGenics (MGNX) Gets a Hold from TD CowenMarch 21, 2025 | markets.businessinsider.comMacroGenics (MGNX) Q4 2024 Earnings Call TranscriptMarch 21, 2025 | msn.comMacroGenics, Inc. (MGNX) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comMacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesMarch 20, 2025 | zacks.comMacroGenics (MGNX) Reports Q4 Loss, Lags Revenue EstimatesMarch 20, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVM, MGNX, EXOZ, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$2.70 -0.03 (-1.10%) As of 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.CEL-SCI NYSE:CVM$0.29 +0.00 (+1.32%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Exozymes NASDAQ:EXOZ$12.05 -1.48 (-10.94%) As of 04:00 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.MacroGenics NASDAQ:MGNX$1.79 +0.08 (+4.68%) As of 04:00 PM EasternMacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
